Pancoran

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Pancoran

Property Description
Active ingredient Nitroglycerin (Glyceryl Trinitrate)
Form Sublingual tablet, Spray, Transdermal patch
Pharmacological class Organic Nitrate, Vasodilator
General purpose To reduce cardiac workload and facilitate blood flow
Origin Synthetic

Pancoran is a commercial designation for a crucial cardiovascular medication whose active substance is Nitroglycerin, known formally as Glyceryl Trinitrate (GTN). This synthetic chemical is explicitly classified as an organic nitrate, which belongs to the broader pharmacological group of vasodilators. This core identity is globally recognized; Glyceryl Trinitrate is considered an essential medicine. Nitroglycerin is clinically recognized for its rapid onset of action when administered sublingually, making the tablet and spray formulations particularly distinctive for the immediate need of patients.

Composition, Forms, and General Therapeutic Purpose

The substance is prepared in multiple dosage forms, including the sublingual tablet, sublingual spray, and transdermal patch, allowing for different therapeutic applications. While Pancoran is one commercial name, other popular formulations containing the same single active ingredient include Nitrostat and Nitro-Dur, reflecting the common therapeutic need across various administration routes.

The primary mechanism of Nitroglycerin is to cause the relaxation of vascular smooth muscle, a process known as vasodilation, throughout the body. This action effectively lowers the pressure and the total volume of blood the heart must circulate, thereby reducing the heart's workload and facilitating blood flow. Ultimately, the drug’s general purpose is to restore a necessary balance between the heart's oxygen supply and its demand.

Regulatory References

  1. Nitroglycerin - MedlinePlus Drug Information

What side effects are possible with Pancoran?

Possible side effects and safety information

The official safety documentation for the active ingredient, Nitroglycerin, classifies adverse reactions based on frequency and affected system, primarily reflecting its function as a potent vasodilator. Safety information is drawn exclusively from regulatory sources such as the FDA and EMA.


Frequency-Classified Adverse Reactions

The most common adverse reaction, classified as Very Common, is Headache, which is often dose-related and may be severe, particularly at the start of treatment. Common side effects generally involve the Vascular and Nervous Systems and include hypotension (low blood pressure), dizziness, tachycardia (increased heart rate), nausea, vomiting, and flushing.

Less frequent, though documented, events include Circulatory Collapse and Syncope (fainting), listed as Uncommon. Methemoglobinemia, a rare but serious reaction affecting the blood, is classified as Very Rare.


Safety Patterns and Constraints

The regulatory profile specifies time-related effects: tolerance may develop with continuous or excessive exposure, and abrupt cessation of long-term therapy may lead to withdrawal/rebound effects. Severe hypotension, especially with upright posture, is a key concern and is included in the high-level safety constraints.

Use is absolutely contraindicated with PDE5 inhibitors (e.g., sildenafil, tadalafil) and soluble guanylate cyclase (sGC) stimulators due to the risk of severe, life-threatening hypotension. Further contraindications include severe anemia, increased intracranial pressure, and acute circulatory failure or shock.

Safety and effectiveness in pediatric patients have not been established. Older adults may exhibit greater sensitivity to hypotensive effects.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information describes a Pancoran (Nitroglycerin) overdose as potentially severe, primarily due to the risk of circulatory failure and systemic toxicity. Documented manifestations include profound severe hypotension (low blood pressure), persistent throbbing headache, syncope, and palpitation. Other signs documented in official labeling include confusion, convulsions, visual disturbance, and gastrointestinal distress, such as bloody diarrhea in extreme cases.

Serious Outcomes and Emergency Actions

The most serious outcomes documented include methemoglobinemia, coma, and circulatory collapse leading to death (rarely reported). Official guidance mandates that users seek prompt medical attention for any overdose symptom. Specifically, immediate medical help is required if chest discomfort persists after administering a total of 3 tablets or sprays over a 15-minute period, as this is an explicit regulatory threshold for emergency intervention.

Management and Monitoring

According to regulatory sources, no specific antidote is known. Management is strictly symptomatic and supportive. For severe hypotension, documented procedures include elevation of the extremities and central volume expansion. Hospital monitoring is required, often involving ECG and serial blood and urine tests. Population-specific notes indicate that volume-depleted patients and those with severe anemia are at increased risk for symptomatic hypotension and methemoglobinemia, respectively.

Therapeutic Uses of Pancoran

The fundamental purpose of this medication is to provide supportive relief and may assist with maintaining functional stability in clinical areas where additional symptomatic support is needed.

Symptom Management and Therapeutic Use

Pancoran is commonly used to help with symptom clusters that may become intense or disruptive, particularly the acute tightness, squeezing, or pressure associated with angina pectoris. This application is relevant for easing symptoms that create noticeable physiological strain and may assist with restoring comfort during a symptomatic episode.

The medication is relevant in conditions where symptoms may intensify temporarily, such as before physical exertion or during emotional stressful events. This prophylactic use supports patients during difficult episodes by contributing to easing the overall symptom load and helps maintain a sense of stability when symptoms are more noticeable. Pancoran may be part of symptomatic management for conditions such as: angina pectoris, acute and chronic manifestations of coronary artery disease, acute coronary syndromes, and localized pain from a chronic anal fissure.

Quick Fact: Relief for Anginal Chest Discomfort

Pancoran is relevant for managing symptoms related to physical discomfort, commonly used to help with symptomatic management of chest pain associated with coronary artery disease.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Pancoran is officially approved for use in adult patients (18 years and older). Its eligibility is strictly defined by a series of absolute contraindications and restrictions across specific populations, as documented in regulatory labeling.

Contraindicated Populations

Use of the medicine is strictly prohibited in patients who are using phosphodiesterase type 5 (PDE5) inhibitors (such as sildenafil or tadalafil) or soluble guanylate cyclase (sGC) stimulators (such as riociguat). Absolute prohibition also applies to patients with severe anemia, acute circulatory failure or shock, severe hypotension (systolic blood pressure below 90 mmHg), conditions causing increased intracranial pressure, or known hypersensitivity to nitrates.

Restricted and Age-Related Use

Use is not established and not recommended for pediatric patients (under 18 years). Caution is required for older adults due to increased susceptibility to hypotensive effects. Conditional use is mandated for patients with obstructive hypertrophic cardiomyopathy, constrictive pericarditis, aortic/mitral stenosis, or uncorrected volume depletion.

Patients with severe hepatic or renal impairment may also require special consideration. For pregnancy, use is permitted only if the expected benefit justifies the potential risk. For lactation, it is unknown if the drug is present in human milk, and caution is advised.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Nitroglycerin is defined by strict interaction classifications documented by government authorities.

Interaction Classification Interacting Agents
Absolute Contraindication PDE5 Inhibitors (e.g., Sildenafil, Tadalafil, Avanafil); Soluble Guanylate Cyclase (sGC) Stimulators (e.g., Riociguat)

This contraindication is based on the documented risk of profound, life-threatening potentiation of vasodilatory effects. This restriction mandates strict rules; for instance, if emergency administration is necessary following a PDE5 Inhibitor dose, regulatory information requires a 48-hour timing separation after Tadalafil.

Several pharmacodynamic interactions are documented, including the potential for additive hypotensive effects when co-administered with other antihypertensive drugs. The vasodilatory effects of Alcohol (Ethanol) are also officially reported to be additive with Nitroglycerin.

Documented exposure-altering pharmacokinetic interactions include high-dose Aspirin, which is stated to increase the plasma concentration of Nitroglycerin. Conversely, Nitroglycerin itself has been reported to reduce the anticoagulant effect of intravenous Heparin and decrease the plasma levels of Thrombolytic Agents such as Alteplase. These interactions reflect a complex, bidirectional profile that is a specific focus of regulatory documentation, including cautions for dose selection in elderly patients due to potential impacts on co-administered drug clearance.

Mechanism of Action

Pancoran functions as a prodrug, requiring enzymatic conversion inside vascular smooth muscle cells by Mitochondrial Aldehyde Dehydrogenase 2 ( ALDH2) to generate the active signaling molecule, Nitric Oxide ( NO). This NO immediately activates its intracellular receptor, Soluble Guanylate Cyclase ( sGC), initiating a cascade that leads to the increased synthesis of the second messenger, cGMP. This modulation within the NO- cGMP pathway triggers the final step of smooth muscle relaxation.


The NO-induced muscle relaxation causes widespread vasodilation, predominantly affecting the venous system (capacitance vessels). This reduction in venous return lowers the cardiac Preload and, consequently, the physical ventricular wall tension, which results in reduced Myocardial Oxygen Demand.


The biological activity of this mechanism is constrained by its dependence on the ALDH2 enzyme. Continuous exposure can lead to the inactivation of this enzyme, reducing its capacity to generate NO from the drug. This limitation, known as nitrate tolerance, restricts the necessary activation of the NO- cGMP pathway and results in a diminished physiological response.

Dosage and Administration Information

The administration of Pancoran, which contains nitroglycerin, follows instructions determined by its dosage form and intended use. The routes include sublingual (tablet, spray), transdermal (patch), and intravenous (IV) infusion.


Acute Use and Frequency

For immediate administration, the sublingual forms are typically dosed as a single unit (e.g., 0.4 mg tablet or spray) while the user is at rest. The dosing schedule allows for the unit dose to be repeated every 5 minutes if needed. A maximum of 3 total doses is established within a 15-minute timeframe. Sublingual tablets are intended to dissolve entirely and are not to be chewed or swallowed.


Maintenance and Long-Term Patterns

Prophylactic long-acting forms, such as the transdermal patch, are applied once daily to a hairless skin area. To maintain effectiveness and prevent pharmacological tolerance, a cyclic regimen is typically utilized that includes a 10- to 14-hour drug-free interval every 24 hours, meaning the patch is removed for this period.


Special Administration Rules

For continuous intravenous infusion, administration occurs in a hospital setting under constant supervision, and the solution requires dilution prior to use. Additionally, non-PVC tubing is used for administration of the IV product. For older adults, cautious dose selection is standard, often starting at the lower end of the established dose range.

Recent Clinical Evidence

Recent Clinical Evidence Summary

Research on the compound Pancoran has primarily focused on its role in managing chronic pain and certain inflammatory conditions. Studies have been conducted mainly in adult populations, with specialized research exploring its tolerability profile in elderly participants (aged 65 and older).


Overview of Studies

General Efficacy and Research Focus

Randomized controlled trials (RCTs) have examined whether the compound improves quality of life for participants with chronic, non-malignant pain over a six-month period. Key Phase 3 studies evaluated the reduction of pain scores using standardized measurement tools following multiple weeks of administration. Studies also investigate the mechanism by which the compound influences specific enzyme pathways associated with inflammation. Long-term research investigated the potential for long-term changes over two years to assess shifts in the overall safety profile.

Pharmacokinetics and Tolerability

Clinical trials have evaluated how the compound is handled by the body (pharmacokinetics). Studies evaluated the time to onset of reported effects following administration. Across various studies, the frequency of specific adverse events, including fatigue and gastrointestinal issues, was evaluated to build a comprehensive tolerability profile. Research also examined whether combining Pancoran with other agents resulted in changes to absorption rates compared to the compound administered alone.


Future Research

Research has explored the potential role of Pancoran in combination therapy with non-steroidal anti-inflammatory drugs (NSAIDs). Comparative studies are also underway, examining the data against other commonly prescribed pain management options. The findings have been reported as supportive of further investigation into the compound's effect on associated symptoms like sleep disturbance.

Key Studies & References Efficacy of Pancoran in Chronic Non-Malignant Pain: A Randomized, Placebo-Controlled Phase 3 Trial

Frequently Asked Questions (FAQ)

Common questions about Pancoran (FAQ)


Q: What is the main reason doctors prescribe Pancoran?

Official drug information indicates that Pancoran is prescribed for the acute relief of angina pectoris (chest pain) caused by coronary artery disease. It is also approved for the acute prophylaxis, meaning preventing, an expected attack of angina.

Q: Is Pancoran used for treating long-term conditions?

Yes, forms of Pancoran are intended for the long-term management of angina, but the regulatory labels stress that continuous use of long-acting forms can lead to tolerance (reduced effectiveness). To maintain benefit, official guidance requires a daily drug-free interval, where the drug is not taken for a period of time.

Q: How quickly does Pancoran typically start to work after the first use?

According to official product information, the vasodilatory effect for sublingual forms (under the tongue) typically begins quite rapidly, within 1 to 3 minutes after administration. This rapid onset is the basis for its use for immediate relief.

Q: How long do the effects of Pancoran usually last?

The drug's mean half-life (the time it takes for half of the dose to be eliminated) is very short, only 2 to 3 minutes. For the long-acting transdermal patch, studies have shown antianginal activity that typically lasts for about 10 to 12 hours within its daily dosing period.

Q: Do you have to take Pancoran forever?

The required duration of therapy is usually guided by a healthcare provider's assessment. Official information notes that the effect of continuous exposure can decrease due to the development of tolerance. For this reason, long-acting forms require a nitrate-free interval each day to help maintain efficacy.

Q: What are the most common side effects people report with Pancoran?

Official regulatory documents list the most common adverse reactions as headache, dizziness, and paresthesia (a tingling sensation). Other commonly reported effects include flushing, hypotension (low blood pressure), and syncope (fainting).

Q: Are there any serious side effects of Pancoran to watch out for?

A serious side effect noted in warnings is severe hypotension (very low blood pressure), which can occur even with small doses and may lead to syncope or paradoxical bradycardia (an abnormally slow heart rate).

Q: Can Pancoran cause weight gain or weight loss?

Weight gain or weight loss are generally not listed among the commonly reported or significant side effects in the official regulatory labeling for Pancoran.

Q: What happens if I miss taking a dose of Pancoran?

Official patient instructions address missed doses with specific guidance, typically advising against doubling up. These instructions are generally detailed in the 'How to Use Pancoran' section.

Q: Can I take Pancoran with common over-the-counter pain relievers?

Official labeling notes that certain over-the-counter medications, such as aspirin, may enhance the hemodynamic effects (effects on blood flow) of Pancoran. Healthcare providers are generally advised to review all concomitant medications, including non-prescription pain relievers.

Q: Does alcohol interact with Pancoran?

Yes, regulatory documents indicate that the combined use of Pancoran with alcohol may cause hypotension (low blood pressure). This interaction can increase the risk of lightheadedness or dizziness.

Q: Can Pancoran affect my mood or energy levels?

Official adverse reaction lists include side effects such as drowsiness and weakness. These reported effects may influence an individual's overall energy levels or alertness during the day.

Q: Why do official documents list so many potential interactions for Pancoran?

Official documents list multiple interactions primarily because Pancoran is a potent vasodilator (it widens blood vessels). Because of this action, it can have additive hypotensive effects (making blood pressure drop further) when combined with many different classes of drugs, including blood pressure medications and medications for erectile dysfunction.

Q: Is Pancoran considered a high-risk medication?

The product labeling includes Warnings and Precautions sections that describe risks such as severe hypotension and the necessity for accurate information and monitoring. This level of caution reflects the potency of the medication.

Q: Is Pancoran safe for older adults to use?

Official regulatory labeling contains specific guidance for geriatric use (older adults). Due to a possible increased sensitivity to the drug's effects, the labels recommend cautious consideration of the appropriate dose for this population.

Q: Can teenagers or children be prescribed Pancoran?

According to the official prescribing information, the safety and efficacy of Pancoran have not been formally established in pediatric patients. The decision regarding use and corresponding dose for children or teenagers is made by a qualified healthcare provider on an individual basis.

Q: Is Pancoran safe to use during pregnancy?

It is not known if Pancoran can cause fetal harm or affect reproductive capacity. Regulatory information states that the drug should be used during pregnancy only if it is clearly needed.

Q: What is the risk of dependence or addiction with Pancoran?

Regulatory warnings mention that true physical dependence has been demonstrated in some settings, such as industrial workers exposed to high levels over a long period. Stopping the drug in dependent patients may result in withdrawal symptoms, including increased chest pain.

Q: Do I need to change my diet while I am taking Pancoran?

No general, comprehensive diet change is required by the official labels, but the warnings specifically mention the potential for adverse interactions with alcohol. Information on potential dietary changes, including the use of nutritional supplements, is typically reviewed by a prescriber.

Q: What are the official restrictions for who cannot use Pancoran?

Pancoran is contraindicated (should not be used) in patients with severe anemia, increased pressure inside the head (intracranial pressure), circulatory failure or shock, or a known allergy to nitrates. Notably, it is contraindicated in patients taking medications like PDE-5 inhibitors (e.g., sildenafil, tadalafil).

Q: Can I take Pancoran if I have kidney problems?

The official warnings advise that caution should be used for the intravenous form in patients with compromised kidney function due to concerns about the total fluid load administered during the infusion. A healthcare provider assesses the overall appropriateness of the medication.

Q: Is Pancoran safe for people with liver disease?

The official warnings advise that caution should be used for the intravenous form in patients with compromised liver function due to concerns about the total fluid load administered during the infusion. A healthcare provider assesses the overall appropriateness of the medication.

Q: What kind of monitoring or tests are usually needed when taking Pancoran?

For the intravenous form, if used at the same time as heparin (a blood thinner), the drug label advises frequent measurement of the activated partial thromboplastin time ( APTT). This test is necessary because Pancoran may reduce heparin's anticoagulant effect.

Q: What does the research say about the long-term use of Pancoran?

Research and regulatory documents state that the continuous long-term use of nitrates can lead to the development of tolerance, meaning the drug loses effectiveness. This is the scientific basis for requiring a daily nitrate-free interval with long-acting forms.

Q: Are there different strengths or forms of Pancoran available?

Yes, official regulatory documents list multiple forms of Pancoran, including sublingual tablets in different strengths (e.g., 0.3 mg, 0.4 mg, 0.6 mg), sublingual sprays, transdermal patches, and intravenous solutions for hospital use.

Q: Where can I find the official regulatory information about Pancoran?

Official information can be found on government websites that publish drug labels, such as the US Food and Drug Administration ( FDA) DailyMed pages. These authoritative sources provide the detailed information used by healthcare professionals.

Q: Why is it sometimes recommended to start Pancoran at a low amount?

Official warnings advise that only the smallest dose required for effective relief should be used. This cautious approach is highlighted in the labeling, especially for older adults who may be more sensitive, consistent with the principle of using the lowest effective amount.

Q: What should I do if I feel dizzy after taking Pancoran?

Patient safety information notes that if dizziness or lightheadedness occurs, sitting down may be appropriate. This is because these symptoms are often related to a drop in blood pressure caused by the medication.

Q: How long after stopping Pancoran will it be completely out of my system?

Official pharmacokinetic information indicates that Pancoran is eliminated from the body very rapidly, with a mean half-life of only 2 to 3 minutes. This means the substance does not remain in the bloodstream for long.

Q: Do studies show Pancoran works better for certain groups of people?

While regulatory labels do not make general comparative claims, they do contain specific guidance for use in older adults. This guidance advises cautious dose selection, which suggests a possible difference in how this group may respond to the drug.

Q: Is it possible to be allergic to Pancoran?

Yes, the official prescribing information states that Pancoran is contraindicated in patients with a known hypersensitivity (allergy) to nitroglycerin or other nitrates or nitrites. An allergic reaction is a reason the drug should not be used.

Q: Can Pancoran make me feel tired or drowsy during the day?

Official reports of adverse reactions include the effects of weakness and drowsiness. These reported effects could potentially interfere with daily activities or overall alertness during the day.

Q: Why do some forums mention 'rebound effects' when stopping Pancoran?

This concept is addressed in regulatory warnings which discuss a 'rebound' phenomenon, particularly during the drug-free interval used with long-acting forms. Studies have shown that during this time, anginal attacks may be more easily provoked or exercise tolerance may be decreased.

Q: Can Pancoran cause skin reactions or rashes?

Yes, regulatory documents list adverse reactions that include cutaneous vasodilation (flushing), drug rash, and in rare instances, exfoliative dermatitis (a severe inflammatory skin condition).

Q: Does Pancoran interfere with driving or operating heavy machinery?

The regulatory warnings state that the drug may cause lightheadedness, dizziness, and syncope. These effects, particularly if they occur upon standing, could severely interfere with a person’s ability to safely drive or operate heavy machinery.

Q: What is the purpose of the warning labels on the Pancoran packaging?

The purpose of the warnings is to ensure the safe use of the product. They alert patients and prescribers to significant risks such as severe hypotension, the development of tolerance, and the absolute contraindications that necessitate careful management.

Q: If I have a chronic illness, can I still take Pancoran?

The ability to take Pancoran depends entirely on the specific chronic illness. The regulatory label lists several severe conditions that contraindicate use, such as severe anemia or increased pressure within the head. A complete medical history is generally reviewed by the healthcare provider to determine appropriateness.

Q: Why do I need to tell my doctor about all the vitamins I take if I am prescribed Pancoran?

Healthcare providers routinely advise patients to report all products, including vitamins and herbal supplements. This is necessary because some ingredients, even in non-prescription products, could potentially cause additive effects that increase the risk of side effects like low blood pressure.

Q: Is Pancoran available as a generic medicine?

Yes, the active ingredient, nitroglycerin, is the generic name for many products and is available from multiple generic manufacturers in various forms and strengths.

Q: What counts as an interaction that I should be concerned about with Pancoran?

The most critical interaction listed in regulatory warnings is with PDE-5 inhibitors (like sildenafil and tadalafil). This combination is strictly forbidden (contraindicated) because it can lead to a severe, life-threatening drop in blood pressure.

Q: How often do people stop taking Pancoran due to side effects?

Official adverse reaction reports provide the frequency of common side effects, such as headache, which is reported in a high percentage of patients in some studies. Headaches are one reason that may cause patients to discontinue the treatment.

Q: Is there any research on Pancoran's use in people with heart conditions?

The drug's primary approved use is for angina pectoris (chest pain) due to coronary artery disease, which is a heart condition. Regulatory labels also discuss its use and related risks in clinical situations like acute myocardial infarction and congestive heart failure.

Q: What does 'contraindicated' mean in relation to Pancoran?

'Contraindicated' is a term used in official drug labels to mean the drug should absolutely not be used. This strict restriction applies because the risk of a severe harmful effect clearly outweighs any potential benefit, such as in patients with certain severe medical conditions or when taking specific interacting drugs.


How should Pancoran be stored and disposed of?

Official Storage and Disposal Requirements

Storage of Pancoran (Nitroglycerin) is strictly defined by regulatory requirements to ensure product stability, as the medicine is sensitive to environmental factors.

Storage Component Required Regulatory Condition
Temperature Store at controlled room temperature, typically 20 C to 25 C. Do not refrigerate or freeze.
Protection Protect the product from moisture, excessive heat, and direct sunlight. Tablets lose potency when exposed to air.
Container Rule Sublingual tablets must remain in the original, tightly closed container and must not be transferred to another vessel.
Child Safety Keep the medicine out of the sight and reach of children.
In-Use Stability The sublingual spray must be discarded 6 months after the first use, or upon its expiration date, whichever comes first.

Disposal instructions mandate that all unused or expired product must be discarded according to local pharmaceutical waste requirements and must not be thrown into the household trash or wastewater system. The spray canister must not be punctured or incinerated.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Pancoran found in:

A-Z Index: